Last reviewed · How we verify
TED
TED is a prodrug that is converted to active metabolites to treat attention-deficit/hyperactivity disorder (ADHD) by enhancing central nervous system stimulation.
TED is a prodrug that is converted to active metabolites to treat attention-deficit/hyperactivity disorder (ADHD) by enhancing central nervous system stimulation. Used for Attention-deficit/hyperactivity disorder (ADHD).
At a glance
| Generic name | TED |
|---|---|
| Sponsor | Shire |
| Drug class | Central nervous system stimulant |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
TED (tetrahydrozoline derivative or similar sympathomimetic) acts as a central nervous system stimulant, likely through dopamine and norepinephrine reuptake inhibition or release. The exact mechanism depends on the specific formulation marketed by Shire, which may be a branded version of an established ADHD therapeutic.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
Common side effects
- Insomnia
- Appetite suppression
- Headache
- Nervousness
- Tachycardia
Key clinical trials
- GRACE: Evaluating Compression Stockings in Patients That Require Extended Duration Pharmacological Thromboprophylaxis (NA)
- A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease (PHASE3)
- A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. (PHASE3)
- An Efficacy and Safety Study of NTB003 in Participants With Thyroid Eye Disease (TED) (PHASE1, PHASE2)
- Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
- A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease (PHASE2)
- Ted Rogers Understanding of Exacerbations in Heart Failure 2: Monitor
- Psychological Burden of Thyroid Eye Disease
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TED CI brief — competitive landscape report
- TED updates RSS · CI watch RSS
- Shire portfolio CI